Latest News


Filter by tags: Medicine Clear all tag filters

28 news articles found

Orano subsidiary Orano Med has laid the foundation stone for its Alpha Therapy Laboratory (ATLab) in Onnaing in northern France. This will be Europe's first industrial-scale pharmaceutical facility dedicated to the production of lead-212 (Pb-212) based radioligand therapies.

Date: Wednesday, 07 February 2024
Original article:

Russia's Ministry of Industry and Trade, representatives from the Kaluga region and the city of Obninsk, and Rosatom have signed a special investment contract for the construction of what Rosatom says will be Europe's largest plant for the production of radiopharmaceuticals.

Date: Wednesday, 11 October 2023
Original article:

The Australian government has officially outlined plans for a new nuclear medicine manufacturing facility at ANSTO’s Lucas Heights campus, replacing an existing facility that is now reaching the end of its operating life. The new facility is expected to be completed by the early to mid-2030s.

Date: Friday, 06 October 2023
Original article:

Advances in emerging field of ‘theranostics’ are a game-changer Millions of patients around the globe rely on the regular and timely production of diagnostic and therapeutic isotopes produced in research reactors and accelerator facilities. Image courtesy IAEA. Advances in medical isotope diagnostics and therapy are holding promise for cancer patients, despite challenges facing the nuclear medical field in recent years related to radionuclide production and supply, rising costs, and stricter regulation.

Medical isotopes are radioactive substances used in various diagnostic and therapeutic procedures to treat various types of cancers and other conditions. They are essential for modern medicine, allowing physicians to visualise and target specific organs, tissues and cells in a patient’s body.

Over more than a decade, personalised medicine using nuclear techniques has been gaining pace, allowing doctors to tailor therapies and treatments to the specific needs and physiology of a patient, and to avoid harm to healthy organs or tissues.

According to Sven Van den Berghe, chief executive of Belgium-based isotope producer PanTera, one technique that has seen significant advances is known as theranostics – the term used to describe the combination of using one radioactive drug to diagnose and a second to deliver therapy to treat the main tumour and any metastatic tumours.

Date: Friday, 14 April 2023
Original article:

President Luis Arce Catacora has delivered the first fluorodeoxyglucose radiopharmaceuticals produced in Bolivia's new Cyclotron Preclinical Radiopharmacy Complex (CRPC) to patients of the Nuclear Medicine and Radiotherapy Centres of El Alto and Santa Cruz.

Date: Saturday, 11 March 2023
Original article:

Pakistan and the International Atomic Energy Agency (IAEA) will increase collaboration in peaceful applications of nuclear science and technology, particularly in agriculture and medicine. This was agreed during a two-day trip to Pakistan by IAEA Director General Rafael Mariano Grossi. Pakistan Prime Minister Shehbaz Sharif and Grossi discussed a range of issues including IAEA support in agriculture and medicine as well as nuclear safety and security.

Date: Thursday, 23 February 2023
Original article:

The aim is to have production lines operating at the plant in Obninsk by 2025, supplying products for the diagnosis and treatment of patients, including a wide range of cancers. Rosatom says it will ensure Russia's sovereignty in the production of radiopharmaceuticals.

Date: Wednesday, 25 January 2023
Original article:

Bangladesh is committed to continuous improvement of nuclear and radiation safety, an International Atomic Energy Agency (IAEA) team of experts has concluded. The Integrated Regulatory Review Service (IRRS) mission team identified areas for possible improvements.

Date: Friday, 16 December 2022
Original article:

The UK National Nuclear Laboratory (NNL) said on 30 May that it had made a breakthrough for producing the medical radioisotope Lead-212, a key cancer treatment, which is difficult to produce. Lead-212 limits the side effects of cancer treatment because it is delivered directly to cancerous cells. Currently the supply of Lead-212 faces a global shortage which constrains its use, with no production route in existence in the UK.

Date: Wednesday, 08 June 2022
Original article: